BACKGROUND: Duarte galactosemia (DG) is frequently detected in newborn-screening programs. DG patients do not manifest the symptoms of classic galactosemia, but whether they require dietary galactose restriction is controversial. We sought to assess the relationships of selected galactose metabolites (plasma galactose, plasma galactitol, erythrocyte (RBC) galactitol, RBC galactonate, and urine galactitol and galactonate) to RBC galactose 1-phosphate (Gal-1-P), dietary galactose intake, and neurodevelopmental/clinical outcomes in DG children.
RESULTS: RBC galactitol and galactonate concentrations were about 2 and 6 times higher, respectively, than control values. Plasma galactose and galactitol concentrations were also about twice the control values. The mean values for RBC Gal-1-P and urine galactitol were within the reference interval. We found a relationship between plasma and urine galactitol concentrations but no relationship between RBC galactose metabolites and urine galactitol. There was a significant relationship between galactose intake and RBC galactose metabolites, especially RBC galactitol (P Ͻ 0.0005) and RBC galactonate (P Ͻ 0.0005). Galactose intake was not related to the urine galactitol, plasma galactose, or plasma galactitol concentration. RBC galactitol, RBC galactonate, plasma galactose, plasma galactitol, and urine galactonate concentrations showed no relationship with clinical or developmental outcomes.
CONCLUSIONS: DG children on a regular diet have RBC Gal-1-P concentrations within the reference interval but increased concentrations of other galactose metabolites, including RBC galactitol and RBC galactonate. These increased concentrations correlate with galactose intake and neither cause any developmental or clinical pathology during early childhood nor oblige a lactose-restricted diet.
Approximately 1 of 4000 Caucasians carries the Duarte-2 mutation (p.N314D) and 1 classic galactosemia mutation of the GALT (galactose-1-phosphate uridylyltransferase) gene. These individuals, so-called DG variants (DG, 4 Duarte galactosemia), typically manifest about 25% of wild-type GALT activity and can be detected through newborn screening (1) (2) (3) (4) . Although these babies have increased concentrations of galactose metabolites, no reports have indicated that such individuals develop symptoms of classic galactosemia (5 ) .
In 2005, we defined the biochemical phenotype of DG children and described 2 different groups of DG children (age, 12-15 months) on a lactose-containing diet according to their erythrocyte (RBC) concentrations of galactitol and galactonate (6 ) . Their RBC galactose 1-phosphate (Gal-1-P) concentrations were within the reference interval; however, this study lacked clinical/neurodevelopmental information and data on dietary galactose intake. We hypothesized that (a) increased RBC concentrations of galactitol and galactonate may be due to an increased dietary galactose intake in some patients and (b) these metabolites may be good markers, in addition to Gal-1-P, for assessing the metabolic burden in galactosemia because they are the products of alternative pathways of galactose metabolism ( Fig. 1 ) and can be found in plasma, RBCs, and urine of both galactosemic and unaffected individuals (7) (8) (9) .
This study tested these hypotheses by measuring the concentrations of several galactose metabolites and then assessing their relationships to RBC Gal-1-P concentration, dietary galactose intake, and neurodevelopmental/clinical outcomes in DG children. The study was performed with approval of the Children's Hospi-tal of Philadelphia Institutional Review Board (no.
2005-8-4364).
We recruited 30 children (15 male and 15 female, 1-6 years of age) with DG galactosemia. All patients were on a regular diet at the time of the study; however, 17 participants had previously been on a lactoserestricted diet in the first year of life. The remaining 13 participants had been on a regular diet since birth. The participants underwent a physical examination, a neurodevelopmental assessment, and an eye examination on the day of the study. Their medical histories were reviewed, and dietary galactose intake was calculated from a 3-day diet record just before the study visit. RBC concentrations of Gal-1-P, galactitol, and galactonate, and plasma concentrations of galactose and galactitol were measured for each participant; liver function tests and coagulation studies also were performed. Urine samples were collected to measure the excretion of galactitol and galactonate. Measurements of RBC galactitol, RBC galactonate, and urine galactonate are not routine clinical tests.
Nonfasting random samples of venous blood and urine were collected from each participant in the morning. Sample preparation and derivatization of RBC Gal-1-P, RBC galactitol, RBC galactonate, plasma galactose, plasma galactitol, urine galactitol, and urine galactonate have previously been described (7) (8) (9) (10) (11) (12) . We also measured RBC and plasma galactose metabolite concentrations in 20 age-matched, nongalactosemic children on a regular diet. Descriptive statistics were evaluated for all outcome measures. The relationships between various biochemical variables were evaluated with Spearman correlation coefficients.
Data for RBC Gal-1-P and urine galactitol were included in a prior report (5 ) .
The RBC concentrations of galactitol, galactonate, and Gal-1-P and the plasma concentrations of galactose and galactitol of 30 DG children on a regular diet were expressed as the mean (SD) ( Table 1) . We found no relationship between age or sex and RBC galactitol, RBC galactonate, plasma galactose, or plasma galactitol concentration. A comparison of these results with those for the nongalactosemic control group revealed that the DG children had (a) a 6-fold higher mean RBC galactonate concentration, (b) a 2-fold higher mean RBC galactitol concentration, (c) a 2-fold higher mean plasma galactose concentration, and (d) a 2-fold higher mean plasma galactitol concentration (Table 1) .
In all DG children, the RBC concentration of galactonate exceeded that of galactitol [mean galactitolgalactonate ratio, 0.02 (0.28)]. The correlation between these metabolites was significant (P Ͻ 0.0005). The mean RBC Gal-1-P concentration was within the reference interval (Table 1 ). These data are expressed both in micromoles per liter to facilitate comparison with other galactose metabolites and in milligrams per deciliter, the unit of measure commonly used by clinical laboratories. The RBC Gal-1-P concentration showed a significant relationship with the RBC galactitol concentration (P Ͻ 0.0005) and with the RBC galactonate GALK, galactokinase; PP, pyrophosphate; UGP, UDP-glucose pyrophosphorylase; GALT, galactose-1-phosphate uridylyltransferase; GALE, UDP-galactose 4-epimerase. 
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Clinical Chemistry 56:7 (2010) 1179 concentration (P Ͻ 0.003). We observed no correlation between the plasma galactose concentration and the plasma galactitol, RBC galactitol, RBC galactonate, or RBC Gal-1-P concentration, nor did we observe any relationship between the plasma galactitol concentration and the RBC concentration of galactitol, galactonate, or Gal-1-P. Table 1 also presents urine concentrations of galactitol and galactonate. The mean urine galactitol concentration of the DG children was within the reference interval, but the mean galactonate concentration was about 2-fold higher than that of the controls (9 ) . Although we did observe a relationship between the urine galactitol concentration and both (a) the plasma galactitol concentration (P ϭ 0.015) and (b) the urine galactonate concentration (P ϭ 0.004), we found no statistically significant relationship between these 2 metabolites and galactose intake or RBC galactose metabolites.
The mean dietary galactose intake was 14 387 (6803) mg/day. Galactose intake was significantly related with RBC galactitol (P Ͻ 0.0005), RBC galactonate (P Ͻ 0.0005), and RBC Gal-1-P (P ϭ 0.02) concentrations. There was no significant correlation between galactose intake and the plasma galactose, plasma galactitol, urine galactitol, or urine galactonate concentration.
The mean values for the 3 outcome variables [adaptive, 103.9 (15.5); language, 109.9 (13.9); and full-scale intelligence quotient, 106.5 (10)] of the 30 study participants were within the reference interval. We evaluated Spearman correlation coefficients for any relationships between a series of galactose metabolites (RBC galactitol, galactonate, and Gal-1-P concentrations; plasma galactose and galactitol concentrations; urine galactitol and galactonate concentrations) and the 3 developmental variables and found no relationships. All of the DG participants had results in liver function tests and the eye examination within the reference interval.
DG children had increased RBC concentrations of galactitol and galactonate, even when the RBC Gal-1-P concentration was within the reference interval. There were significant correlations among RBC Gal-1-P, galactonate, and galactitol concentrations. This result is interesting for 2 reasons: (a) The same relationship was not reported in patients with classic galactosemia (10 ) , and (b) these 3 metabolites reflect different metabolic pathways and metabolic fates. Gal-1-P is formed in the Leloir pathway via galactokinase and cannot be metabolized further, owing to diminished GALT activity. Gal-1-P can be formed endogenously from UDPgalactose and is dephosphorylated by phosphatases to galactose (13, 14 ) . Galactitol is formed in RBCs and is neither further metabolized nor readily diffusible across cell membranes (1 ). It is possible that RBC galactitol derives in part from the plasma pool. Galactonate is formed via oxidation of galactose by galactose dehydrogenase and converted in the liver to CO 2 and a 5-carbon sugar (15 ) . We do not know whether this biochemical reaction occurs in RBCs and whether galactonate diffuses into the plasma.
There was no correlation between the plasma concentrations of galactose and galactitol, suggesting that they derive from different sources. Galactose is derived primarily from the diet and to a lesser degree from the endogenous turnover of complex carbohydrates. Galactitol is produced from galactose intracellularly by aldose reductase with variable leakage into the plasma. The formation of galactitol is dependent on the activity of aldose reductase, which may vary among individuals.
We found no correlation between the plasma concentration of galactose and the RBC concentration of galactitol, galactonate, or Gal-1-P, nor did we observe a relationship with plasma galactitol. Perhaps the absence of a correlation reflects differing enzyme activities, such as those of aldose reductase, galactokinase, and/or galactose dehydrogenase.
We found that galactose intake was significantly correlated with RBC galactitol, RBC galactonate, and RBC Gal-1-P concentrations (see above), although the correlation of galactose intake with the RBC Gal-1-P concentration was weaker than with the RBC concentrations of galactitol and galactonate. Galactose intake was not correlated with the plasma galactose, plasma galactitol, urine galactitol, or urine galactonate concentration. These data reveal that the RBC concentrations of galactitol and galactonate appear to be sensitive metabolites for assessing the galactose burden in DG children.
Of interest is the absence of a relationship between galactose intake and urine galactitol, which is commonly used to monitor the adequacy of diet therapy. Similarly, we could not document a correlation between the urine galactitol concentration and the RBC Gal-1-P, RBC galactitol, RBC galactonate, or plasma galactose concentration. This finding raises the question of the efficacy of measuring galactitol in spot urine for monitoring metabolic control in DG galactosemics.
We found no correlation between clinical or developmental outcomes and RBC galactitol, RBC galactonate, plasma galactose, plasma galactitol, and urine galactonate concentrations. The DG children had mildly increased RBC galactitol and plasma galactitol concentrations, however. If these concentrations persist, such patients may be at a higher risk of having presenile cataracts in later life. In 2003, we described a 38-year-old woman with DG galactosemia who developed bilateral presenile cataracts. The finding in this single case report (and to our best knowledge, no others have been reported) may be coincidental, because the frequency of the DG genotype is common in the population (16 ) . Further studies are warranted to assess the risk of presenile cataracts over the life course of older DG individuals.
Physicians who advocate a lactose-restricted diet for DG galactosemia often use the RBC Gal-1-P concentration as a metric to decide whether patients should continue the diet after 1 year of age. We have found that the RBC Gal-1-P concentration can be within the reference interval when the concentrations of other galactose metabolites are increased. It is true that increased concentrations of these metabolites denote an abnormal galactose burden, but they seem to have no clinical consequences during early childhood and do not oblige diet therapy in DG galactosemia.
In 2003, Yager et al. showed that patients with classic galactosemia on a galactose-restricted diet had increased RBC concentrations of Gal-1-P, galactitol, and galactonate (10 ) . In healthy individuals and DG galactosemics, RBC concentrations of galactonate were higher than for galactitol; however, these investigators reported the opposite finding in patients with classic galactosemia: RBC concentrations of galactitol higher than for galactonate (10 ) . Although their study did not analyze the relationship between dietary galactose intake and RBC galactose metabolites, it suggested that measuring RBC concentrations of galactitol and galactonate along with Gal-1-P might augment the monitoring of the galactose metabolic status of galactosemics. What remains to be explained for future research is (a) why patients with classic galactosemia have a higher galactitol-galactonate ratio than DG galactosemics and healthy individuals and (b) whether measuring the RBC concentrations of galactitol and galactonate along with Gal-1-P is clinically valuable for assessing the galactose burden in classic galactosemics.
Our data show that DG children between 1 and 6 years of age have RBC Gal-1-P values within the reference interval but increased concentrations of other galactose metabolites, including RBC galactitol and galactonate, that correlate with galactose intake. These increased concentrations neither cause any detectable developmental or clinical pathology during early childhood nor oblige a lactose-restricted diet. In DG children, galactose intake correlates more strongly with the RBC concentrations of galactitol and galactonate than with the RBC Gal-1-P concentration. This result suggests that RBC galactitol and galactonate may be more sensitive markers than RBC Gal-1-P for assessing dietary galactose intake in patients with GALT enzyme deficiency. These results may not be as straightforward as they appear, however. They may also be influenced by 2 additional factors that require further study: (a) the de novo synthesis of galactose in body tissues and fluids and (b) the daily time-dependent changes in blood galactose concentrations linked to diet intake. 
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